Addendum:

A new role under sortilin’s belt in cancer.

Cornelia M. Wilson\textsuperscript{a,b}, Thomas Naves\textsuperscript{b}, Hussein Al-Akhrass\textsuperscript{b}, François Vincent\textsuperscript{b,c}, Boris Melloni\textsuperscript{c}, François Bonnaud\textsuperscript{d}, Fabrice Lalloué\textsuperscript{b}, Marie-Odile Jauberteau\textsuperscript{b}

\textsuperscript{a}University of Liverpool, Institute of Translational Medicine, Dept of Molecular & Clinical Cancer Medicine, Liverpool, L7 8TX

\textsuperscript{b}EA3842 Homéostasie cellulaire et pathologies and Chaire de Pneumologie Expérimentale, Université de Limoges, Faculté de Médecine, 2, rue du Dr Raymond Marcland, 87025 Limoges CEDEX–France

\textsuperscript{c}Service de Pathologie Respiratoire, Centre Hospitalier et Universitaire de Limoges, 87000 Limoges CEDEX-France.

*To whom correspondence should be addressed.

E-mail: Cornelia.Wilson@liverpool.ac.uk/cornelia.wilson@unilim.fr

Running title: Sortilin in cancer

Total character count: (no spaces): 9,466
Title: A new role under sortilin’s belt in cancer.

Abstract:

The neurotensin receptor-3 also known as sortilin was the first member of the small family of vacuolar protein sorting 10 protein domain (Vps10p) discovered two decades ago in the human brain. The expression of sortilin is not confined to the nervous system but sortilin is ubiquitously expressed in many tissues. Sortilin has multiple roles in the cell as a receptor or a co-receptor, in protein transport of many interacting partners to the plasma membrane, to the endocytic pathway and to the lysosomes for protein degradation. Sortilin could be considered as the cell’s own shuttle system. In many human diseases including neurological diseases and cancer, sortilin expression has been shown to be deregulated. In addition, some studies have highlighted that the extracellular domain of sortilin is shedded into the culture media by an unknown mechanism. Sortilin can be released in exosomes and appears to control some mechanisms of exosome biogenesis. In lung cancer cells, sortilin can associate with two receptor tyrosine kinase receptors called the TES complex found in exosomes. Exosomes carrying the TES complex can convey a microenvironment control through the activation of ErbB signaling pathways and the release of angiogenic factors. Deregulation of sortilin function is now emerging to be implicated in four major human diseases- cardiovascular disease, Type 2 diabetes mellitus, Alzheimer’s disease and cancer.

Keyword: Sortilin/TrkB/EGFR/exosome/lung cancer/

Exosomes discovery timeline: Exosomes are small extracellular vesicles (“cell bubbles”) secreted by most eukaryotic cells. They range from 30 to 100nm in size found in the cell culture media and many biological fluids such as blood, saliva and urine, and hence have a potential involvement in intercellular communication. They were originally described in 1983 such as small released vesicles from the multivesicular body (or also known as multivesicular late endosome) fusion with the plasma membrane during red blood cell maturation \(^1\) (Figure 1). For many years these vesicles were believed to be the cell’s own garage disposal route. Some years later, these scarcely understood microvesicles have been called exosomes. \(^2\) Since the last decade, exosomal research is growing exponentially, especially after the discovery of distinct subsets of RNAs into the exosomal cargo \(^3\), which has enriched the knowledge of the molecular cocktail that may be shuttled by exosomes. In doing so, many laboratories have investigated the close link between exosome secretion and disease, indicative but not exhaustive, such as cardiomyocyte hypertrophy \(^4\), diabetes \(^5\) and cancer. \(^6-8\) Remarkably, cancer cells may take advantage of exosome secretion in order to control the tumor microenvironment, and could endorse thereby the aggressiveness and the tumorigenic features of the tumor, such as angiogenesis \(^6\), invasion \(^8, 9\) and therapeutic escape \(^7\). Encouragingly, exosomes are shedding light on their utility as disease diagnostic markers \(^10, 11\), as well as in
the development of novel cancer treatment, and could take the lion’s share of this major challenge.

**Sortilin:** Sortilin is a newly identified member of a small family of proteins characterized to contain a Vps10p domain. Sortilin can function alone or as part of a co-receptor as well as a transporter of proteins from the trans-Golgi network (TGN). As a co-receptor of p75 neurotrophin receptor (p75NTR), sortilin binds the immature, pro-forms of nerve growth factor (NGF) or brain derived neurotrophic growth factor (BDNF) and induces apoptosis in neuronal cells. Sortilin’s cytoplasmic tail shares similarity to the mannose-6-phosphate receptor with colocalisation to the endosomes and endosome to TGN cargo vesicles. In addition, sphingolipid activator proteins, acid sphingomyelinase, and cathepsin D and H have been shown to be trafficked by sortilin to the lysosomes. These studies demonstrate that sortilin has a dual role both in endocytosis and in receptor trafficking allowing the correct sorting of ligands from the cell surface to lysosomes and the traffic of pro-neurotrophins (proNTs) such as the neuropeptide neurotensin (NT), proNGF and proBDNF.

**Role of sortilin in cancer:** Given the important function of pro-neurotrophin receptors such as sortilin play in cellular development, cell survival and death. An imbalance in cellular homeostasis can be affected by neurotrophin signalling which could lead to the progression of cancer. Not surprising, sortilin expression is elevated in several human cancer cells including brain, prostate, colon, pancreas, skin, pituitary. Some of the initial studies demonstrated that a furin-cleaved form of sortilin could bind NT at the cell surface and traffic NT to the endocytic pathway whilst maintaining a constant level of sortilin expression at the cell surface. In a later study, sortilin was shown to be released from cells requiring cleavage of sortilin luminal domain by a protein kinase C-dependent protease. However, the mechanism used for sortilin release from these cells and the consequence to the microenvironment was uncertain. In colon cancer, sortilin forms a dimeric complex with NTSR1 which is internalised upon NT stimulation. The binding of NT to sortilin-NTSR1 and trafficking of this complex induces signaling pathways by modification of mitogen-activated protein (MAP) kinases and the turnover of phosphoinositide (PI) facilitated by NTSR1. It is not known why sortilin is released from cancer cells but evidence is now emerging to implicate that sortilin may modify the neighbouring cells/environment. Massa and colleagues studied the human adenocarcinoma epithelial cell line (HT29) to assess the ability of soluble sortilin to be released and internalised using radioreceptor assays and microscopy. The binding of soluble sortilin is independent from the transactivation of the epidermal growth factor receptor (EGFR) resulting in raised intracellular calcium concentration and significant activation of PI3 kinase pathway through Akt phosphorylation dependent upon of FAK/Src phosphorylation. The PI3 kinase pathway is implicated in the survival mechanisms of cancer cells. The action of soluble sortilin could be explained to have an autocrine/paracrine function.
A number of reports have hinted that NT mediated by sortilin stimulated by an autocrine/paracrine function could be a mechanism associated with the tumorigenesis.\textsuperscript{26-28} The cell responds to two types of neurotrophin signal, one elicited by the p75\textsubscript{NTR} and the other by Trk tyrosine kinase receptors.\textsuperscript{34} Sortilin can interact with either of these receptors but the consequential outcome affects cell survival. Sortilin traffics from the TGN to the cell surface through the secretory pathway where it interacts with p75\textsubscript{NTR} that can signal a pro-neurotrophin-induced cell death. The signals induce cell death by the pathway of c-Jun N-terminal kinase 3 and caspases 3, 6 and 9.\textsuperscript{35-38} Trk interaction with sortilin promotes cell survival and in the case of neuronal cells stimulates cell survival, differentiation, innervation and plasticity /effect cell survival. Sortilin can associate with all the Trk receptors (A, B and C)\textsuperscript{24, 25} implicating an important role in cell survival that is disrupted in human disease.

**Sortilin is a key component of exosome biogenesis.** Unprecedented reports have found that sortilin expression level is associated to different types of cancer.\textsuperscript{26-28} Some of these studies have implicated that sortilin could play a role in the tumorigenesis process.\textsuperscript{26, 27} Our team has been interested in these links between sortilin and cancer and at the same time the cross-talk between the epidermal growth factor receptor (EGFR) and tyrosine kinase receptor (Trk) signalling pathways.\textsuperscript{13} We have discovered that sortilin can form a novel complex with TrkB and EGFR found in exosomes that are released from lung cancer cells conveying a microenvironmental control upon endothelial cells.\textsuperscript{39} In this study, we examined closely the secretion mechanism utilised for the extracellular domain of sortilin from human lung cancer cells (A549) and the effect on the microenvironment. We show for the first time that sortilin uses a ‘canonical pathway’ and can be found in exosomes. We demonstrate that sortilin is a key component of exosomes mediating communication between A549 and endothelial cells (Figure 2). Sortilin is already known to play a prime function in cancer cells; however we have reported herein that it plays a new role in both the assembly of a tyrosine kinase complex and its exosome release. This novel complex called ‘TES’ complex expressed by exosomes results in the linkage of two tyrosine kinase receptors, TrkB and EGFR with sortilin. We demonstrate in this study that the TES complex coveys a control on the microenvironment i.e. endothelial cells and initiates the activation of angiogenesis via exosome transfer. Therefore, our data suggested that sortilin and its partners have a paracrine through exosome transfer and control of the microenvironment. This novel complex containing sortilin could play the role as a molecular switch in cancer progression by promoting angiogenesis.

**The unanswered questions of sortilin’s role in exosome/EV biogenesis.** It is well appreciated that MVBs have two fates in the cell; they act as a platform to deliver cargo destined for lysosome-mediated degradation or as a portal to release ILVs/exosomes from the cell. The endosomal sorting of cargo is mediated by a sequence events involving four multiprotein complexes (ESCRT0, -I, -II, and –III). The clathrin coats condense and cluster cargo at the cytosolic face of the MVB membrane ready to be captured and recruited to ILVs. These early events of cargo recruitment are assisted by the ESCRT machinery, ESCRT-0 and ESCRT-I. In a previous study, the HRS gene found in the ESCRT-0 complex could be involved in the formation and secretion of exosomes.\textsuperscript{40} Knocking down some of the genes
that encode for components of the ESCRT-0 complex (HRS, STAM1 or TSG101) perturb exosome release and affect the size and/or protein content of the ILVs demonstrating an important role played by the ESCRT complex.\textsuperscript{41} Our data suggested a possible unreported new role for sortilin as a possible cargo recruiter to ILVs through cargo recognition and sorting at the MVB. The challenge remains to determine several questions: (1) what is the intracellular route of sortilin trafficking through the secretory pathway; (2) at what stage is sortilin important for ILV formation at the MVB; (3) what is sortilin’s mechanism to recruit cargo or the regulation of ILV formation; (4) and at the same time whether sortilin released as exosomes from cells plays a role in the angiogenesis process. Furthermore, an imbalance in sortilin expression in cancer could alter the content of exosomes regulating the delivery of both a genomic and proteomic content to the target cells. To this end, the challenge remains to define the exact role of sortilin in cancer thus providing clues to sortilin’s global role in other types of human diseases.
**Figure 1** Main discoveries in extracellular vesicle biology

Timeline showing the main discoveries in the extracellular vesicle research.

**Figure 2** Role of sortilin in EV biogenesis

Sortilin is initially synthesised in the constitutive secretory pathway as a precursor encoding a short propeptide sequence. The propeptide is cleaved by pro-protein convertases at the TGN allowing sortilin to enter the secretory pathway (stage 1). There are a number of likely routes that sortilin could be trafficked. Sortilin can be trafficked along a number of possible routes such as trafficking to the plasma membrane through constitutive secretory vesicles (stage 2). Alternatively, sortilin could be anterograde transported from the TGN by itself or with its binding partners to the early endosomes (stage 3). Sortilin present at the cell surface or in the endocytic pathway could be cleaved by disintegrin and metalloproteinase domain-converting protein (ADAM) 10 or ADAM17, and followed by γ-secretase (stage 5). Following endoproteolytic cleavage, sortilin could form a heterotrimeric complex with TrkB and EGFR (TES complex) which is internalized through a clathrin-dependent endocytosis process into early endosomes (stage 6). At the plasma membrane, the purple spots represent clathrin associated with vesicles (clathrin-coated vesicles [CCV]) or the bilayered clathrin coats at the endosome. The intraluminal vesicles (ILV) are formed by an invagination event at the membrane of the late endosomes/multivesicular body (MVB). Sortilin may play a role in the recruitment of certain cargo such as its binding partners- TrkB and EGFR, which could be an ESCRT-dependent mechanism. The MVB and its content could be degraded via the lysosome-mediated pathway for degradation or alternatively the MVB are transported to the cell surface where they dock at the plasma membrane requiring Rab27A to release the vesicles into the extracellular space (stage 7). The exosomes carrying the TES complex could be released and taken up in the target cell. The uptake of TES-containing exosomes initiates cellular communication through upregulation of cell signaling events by the induction of cell survival through the EGFR cascade and the angiogenesis process (stage 8).

**References:**


Figure 1

Exosome discovery timeline


Membrane enclosed vesicles
Anderson et al., 1969 (cartilage)
Crawford et al., 1971 (blood)
Stegmayr and Ronquist, 1982 (sperm)

Cells shed vesicles
Dvorak et al., 1981 (tumour cells)
George et al., 1982 (platelets)
Trams et al., 1982 (mammalian cells)

Intercellular communication
Raposo et al., 1996
Zievogl et al., 1997

Rab proteins involved in exosome release
Savina et al., 2002 (Rab11)
Ostrowski et al., 2010 (Rab27)
Hsu et al., 2010 (Rab35)
Yang et al., 2015 (Rab3D)

Recombinant exosomes
Alvarez-Erviti et al., 2011 (Tissue specific targeting shRNA to the brain)

miRNA profile and tumoural signature
- GBM (Henriksen M. et al, 2014; Manterola L. et al., 2014)
- Breast (Kruger S. et al., 2014)
- Colorectal (Ogata-Kawata H et al., 2014)
- Melanoma (Xiao D. et al., 2012)
- Lung (Leidinger P. et al., 2014)
- Ovarian (Vaksman O. et al., 2014)

Multivesicular body (MVB)
Harding et al., 1993
Pan and Johnstone, 1983

‘Exosome’ coined as the cells garbage system
Johnstone et al., 1987

Transfer of genetic material (mRNA, miRNA)
Valadi et al., 2007
Mitchell et al., 2008
Skog et al., 2008
Ohshima et al., 2010

Proangiogenic activities mediated through exosome transfer
Al-Nedawi et al., 2008 (Glioblastoma)
Peinado et al., 2012 (educating bone marrow progenitor cells)
Figure 2

Microenvironment

Plasma membrane

Cell signaling

TES complex

Sor4lin

CCV

Constitutive secretory granule

ESCRT dependent?

Sortilin

trans-Golgi Network

Early Endosome

MVB

Lysosome

Angiogenesis

Cell survival

Rab27A

Exosomes

Figure 2 CCV